TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02544893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: 21 ml 0.5 %bupivacaine is applied paravertebral space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidin
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serum physiologic
Description: 21 ml serum physiologic is applied paravertebral space
Study: NCT00879671

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lutamax (leutein)
Description: leutein 20 mg for 3 months, then lutein 10 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsules identical in taste and appearance
Study: NCT02517905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Local administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration
Study: NCT03135522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate 50 Mg Oral Capsule
Description: * Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: * Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)
Study: NCT01678534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic mesenchymal stem cells from adipose tissue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04546854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appeals
Description: Written text motivating participants to take up the seasonal influenza vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appeals
Description: Written text motivating participants to take up the seasonal influenza vaccination
Study: NCT03258372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
Study: NCT02309281

Intervention type: DRUG
Group type: OTHER
Intervention: aflibercept 2mg
Description: Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
Study: NCT01114516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin and antibiotics (cefazolin or clindamycin)
Description: q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
Study: NCT03211741

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab Injection [Avastin]
Description: Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
Study: NCT04090814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeatTens (HV-F311-E)
Description: (1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
Study: NCT01839708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
Study: NCT03102606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D5W Placebo
Description: Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
Study: NCT05471999

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: interventional or surgical treatment
Study: NCT00218023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl
Description: Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
Study: NCT04742595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
Description: Given IV
Study: NCT03495752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bruce Fatigue Protocol
Description: Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
Study: NCT06425601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIL drain
Description: Silicone chest tube used for pleural space drainage after VATS lobectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC drain
Description: Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
Study: NCT01299428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS 5100
Description: INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
Study: NCT03184402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1252
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gasmotin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Gasmotin
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of DWJ1252
Description: tablet
Study: NCT03172715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locking plate
Description: Osteosynthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKR
Description: Total knee arthroplasty
Study: NCT02087462

Intervention type: OTHER
Group type: OTHER
Intervention: Electroacupuncture (EA)
Description: Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Electroacupuncture (EA)
Description: Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Description: Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks.
Study: NCT00218023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
Study: NCT00440193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin followed by VKA
Description: Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Study: NCT04278872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJX-653
Description: administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally once daily
Study: NCT02087462

Intervention type: OTHER
Group type: OTHER
Intervention: Traction
Description: An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.

Intervention type: OTHER
Group type: OTHER
Intervention: Traction
Description: An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.

Intervention type: DRUG
Group type: OTHER
Intervention: Voltaren
Description: Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin B1
Description: Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks.
Study: NCT04309435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-esteem intervention
Description: See relevant study arm for description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-stigma intervention
Description: See relevant study arm for description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping to conclusions intervention
Description: See relevant study arm for description

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control procedure (assessment only)
Description: See relevant study arms for description
Study: NCT03793309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral vitamin D
Study: NCT04309435

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control procedure (assessment only)
Description: See relevant study arms for description

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control procedure (assessment only)
Description: See relevant study arms for description
Study: NCT00431249

Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol
Study: NCT00583427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: 200 mg per day in an oral gelcap form
Study: NCT02526017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Solution for IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Solution for IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Solution for IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Solution for IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Solution for IV administration
Study: NCT05219032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Medical Interpreter
Description: A professional medical interpreter accompanies patient to each appointment.
Study: NCT04540315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MobiMD
Description: MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
Study: NCT01920841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream A applied to left thigh and Cream B to right thigh
Description: Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream B applied to left thigh and Cream A to right thigh
Description: Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
Study: NCT04261153

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive stimulation
Description: 3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
Study: NCT03542929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
Study: NCT02874820

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]BU99008
Description: Baseline and blocked scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idazoxan
Description: Idazoxan dose up to 80mg
Study: NCT02145949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA)
Description: Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Alanine)
Description: Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
Study: NCT02959398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mammography
Description: Standard mammography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard mammography and tomosynthesis
Description: Standard mammography and tomosynthesis
Study: NCT02393066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation
Study: NCT02867748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-Abbrevo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serasis
Study: NCT00995462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention seminars
Description: The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
Study: NCT00787410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: 250mg tablet, once daily, orally administered
Study: NCT00385970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-uracil (UFT)
Description: From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (UFT)
Description: From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium folinate (LV)
Description: From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin (PSK)
Description: From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
Study: NCT00572650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: 16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
Study: NCT01745029

Intervention type: DEVICE
Intervention: Motilis-3D-transit
Study: NCT03683381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health
Description: Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Participants in the Patient education group will receive weekly information on insomnia symptoms
Study: NCT00110266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20 mg/kg/day over one year in patients with MDS
Study: NCT01305460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study.
Study: NCT03340246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed sclerotherapy
Description: See arm descriptions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate phlebectomy
Description: See arm description